Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an important nosocomial pathogen in recent decades, being responsible for an increasing proportion of patients with Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). On the other hand, many areas in the world have experienced an alarming emergence of infections and particularly pneumonias caused by the so-called Community-Acquired MRSA (CA-MRSA), a genetically distinct strain, which shares common clinical and microbiological features with nosocomial MRSA. This paper reviews the latest epidemiological and therapeutic data and discusses currently available and future treatment options. A recent significant epidemiological feature is the “creep” observed in vancomycin minimal inhibitory concentrations. As new clinical and PK data are available relating to the use of vancomycin and linezolid, which have both been first-line options in the treatment of MRSA pneumonia in the last decade, recently issued guidelines and arguments for their revision are discussed.
Keywords: Antimicrobials, CA-MRSA, linezolid, MRSA, pneumonia, vancomycin, pathogen, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, mecA gene
Current Respiratory Medicine Reviews
Title:Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Volume: 8 Issue: 3
Author(s): Garyphallia Poulakou, Jessica Souto, Nina Kmet Lunacek and Jordi Rello
Affiliation:
Keywords: Antimicrobials, CA-MRSA, linezolid, MRSA, pneumonia, vancomycin, pathogen, Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, mecA gene
Abstract: Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an important nosocomial pathogen in recent decades, being responsible for an increasing proportion of patients with Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). On the other hand, many areas in the world have experienced an alarming emergence of infections and particularly pneumonias caused by the so-called Community-Acquired MRSA (CA-MRSA), a genetically distinct strain, which shares common clinical and microbiological features with nosocomial MRSA. This paper reviews the latest epidemiological and therapeutic data and discusses currently available and future treatment options. A recent significant epidemiological feature is the “creep” observed in vancomycin minimal inhibitory concentrations. As new clinical and PK data are available relating to the use of vancomycin and linezolid, which have both been first-line options in the treatment of MRSA pneumonia in the last decade, recently issued guidelines and arguments for their revision are discussed.
Export Options
About this article
Cite this article as:
Poulakou Garyphallia, Souto Jessica, Kmet Lunacek Nina and Rello Jordi, Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review, Current Respiratory Medicine Reviews 2012; 8 (3) . https://dx.doi.org/10.2174/157339812800493250
DOI https://dx.doi.org/10.2174/157339812800493250 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacology of Cyclic Peptides: Vancomycin and Oxytocin as Paradigms
Protein & Peptide Letters Novel Antimicrobial Agents Against Multi-drug-resistant Gram-positive Bacteria: An Overview
Recent Patents on Anti-Infective Drug Discovery In Vitro Synergistic Action of Certain Combinations of Gentamicin and Essential Oils
Current Medicinal Chemistry Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Aminoglycoside Nephrotoxicity
Current Drug Targets - Infectious Disorders <i>In Vitro</i> Evaluation of Immunogenicity of Recombinant OMP25 Protein Obtained from <i>Endemic Brucella</i> abortus Biovar 3 as Vaccine Candidate Molecule Against Animal Brucellosis
Protein & Peptide Letters Discovery of Medically Significant Lantibiotics
Current Drug Discovery Technologies The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Neuroprotective Effects of Ginkgolide B Against Ischemic Stroke: A Review of Current Literature
Current Topics in Medicinal Chemistry Current Status of Molecular Imaging in Infections
Current Pharmaceutical Design Appropriate Utilization of Restricted Antibiotics in a General Hospital of a Perfecture Area in Greece
Current Drug Safety New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?
Current Drug Metabolism Contraception in Women with Medical Conditions
Current Women`s Health Reviews Immunopathological Aspects of Mycoplasma pneumoniae Infection
Current Pediatric Reviews Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets Acute Tonsillitis
Infectious Disorders - Drug Targets